Johns Hopkins Bloomberg School of Public Health

Dr. Durbin received her Bachelor of Science in Pharmacy from the University of Michigan, Ann Arbor Michigan and her M.D. from Wayne State University in Detroit Michigan. She is certified in the specialties of Internal Medicine and Infectious Diseases. Following her fellowship in infectious diseases, Dr. Durbin became a Medical Officer at the Laboratory of Infectious Diseases at the National Institutes of Health where she spent 5 years using recombinant DNA technology to develop novel live attenuated respiratory virus vaccines. She left the NIH to become a tenure-track faculty in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health where she is currently as associate professor.

She is the Principal Investigator of a National Institutes of Health contract to evaluate novel malaria vaccines and is the co-principal investigator for a contract to evaluate vaccines and antimicrobials in adults and pediatric subjects. She has served as the Principal Investigator for numerous clinical trials evaluating the safety and immunogenicity novel live attenuated dengue vaccine candidates. These trials have led to the identification of a live attenuated tetravalent dengue vaccine that is currently being evaluated in in flavivirus-naïve and flavivirus-experienced volunteers in Brazil and Thailand and has begun Phase 3 efficacy trials in Brazil. She has, in collaboration with NIH scientists, developed a controlled dengue human infection model (CHIM) to down-select candidate dengue vaccines prior to the initiation of large-scale efficacy trials in endemic areas. She has served on FDA and WHO vaccine advisory committees.

Dr. Durbin received a National Institutes of Health Merit Award in 2005, a National Institutes of Health Director's Award in 2011 and the Instituto Butantan medal, Sao Paulo Brazil, in 2013. She has published more than 70 peer-reviewed papers.